The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended several changes to the way the antibiotic azithromycin is used in the EU, including the removal of certain ...

Christophe Delenta, President Europe, Sandoz, said: “Access to medicine does not end when it reaches the hands of the patient. The Pyzchiva® autoinjector, with its thoughtful and advanced ...

Autoinjector includes unique features to improve comfort, independence and convenience for patients with chronic inflammatory diseases [1-10] Launch strengthens Sandoz biosimilar leadership position ...

Sandoz, one of the global leaders in generic and biosimilar medicines, announced the European launch of its Pyzchiva (ustekinumab) autoinjector. This is the first ustekinumab biosimilar in Europe ...

Christophe Delenta, President Europe, Sandoz, said: "Access to medicine does not end when it reaches the hands of the patient. The Pyzchiva® autoinjector, with its thoughtful and advanced ...

Azithromycin has been widely evaluated for its efficacy against COVID-19. The study by Timothy S C Hinks and colleagues1 adds value to the current literature, and we would like to share our comments.

After months of deliberation, and no formal offers from a buyer, Novartis has decided that its generics business Sandoz will be spun out into an independent company. The Swiss pharma group said ...

53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars in USStrengthens US immunology ...

The 20-mg/kg/day dose of azithromycin for 3 days may also be better than the 10-mg/kg/day dose for 3 days in terms of minimizing the risk of emerging resistance in the GABHS. [35,43] Using the ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...

Abia State Government has called for the sustainability of Safety and anti-miccrobial resistance of mass administration of azithromycin among children aged 1-11 months in Nigeria 1 project in the ...